scholarly journals Circulating Cell-Free DNA Correlates with Body Integral Dose and Radiation Modality in Prostate Cancer

2020 ◽  
Vol 7 (2) ◽  
pp. 21-30
Author(s):  
Natalie A. Lockney ◽  
Randal Henderson ◽  
Steven G. Swarts ◽  
Zhenhuan Zhang ◽  
Bingrong Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Field Size ◽  
Cell Free Dna ◽  
Integral Dose ◽  
Prostate Bed ◽  
Free Dna ◽  
Patient Reported ◽  
To Receive ◽  
Circulating Cell Free Dna

Abstract Purpose The RadTox assay measures circulating cell-free DNA released in response to radiotherapy (RT)-induced tissue damage. The primary objectives for this clinical trial were to determine whether cell-free DNA numbers measured by the RadTox assay are (1) correlated with body integral dose, (2) lower with proton RT compared with photon RT, and (3) higher with larger prostate cancer RT fields. Patients and Methods Patients planned to receive proton or photon RT for nonmetastatic prostate cancer in the setting of an intact prostate or postprostatectomy were eligible for the trial. Plasma was collected pre-RT and at 5 additional daily collection points beginning 24 hours after the initiation of RT. Data from 54 evaluable patients were analyzed to examine any correlations among RadTox scores with body-integral dose, RT modality (photon versus proton), and RT field size (prostate or prostate bed versus whole pelvis). Results Body integral dose was significantly associated with the peak post-RT RadTox score (P = .04). Patients who received photon RT had a significant increase in peak post-RT RadTox score (P = .04), average post-RT RadTox score (P = .04), and day-2 RadTox score (all minus the pre-RT values for each patient) as compared with patients who received proton RT. Field size was not significantly associated with RadTox score. Conclusion RadTox is correlated with body integral dose and correctly predicts which patients receive proton versus photon RT. Data collection remains ongoing for patient-reported RT toxicity outcomes to determine whether RadTox scores are correlated with toxicity.

scholarly journals Measuring Radiation Toxicity Using Circulating Cell-Free DNA in Prostate Cancer Patients

2021 ◽  
Author(s):  
Natalie A. Lockney ◽  
Randal H. Henderson ◽  
Steven G. Swarts ◽  
Zhenhuan Zhang ◽  
Bingrong Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Toxicity ◽  
Cell Free Dna ◽  
Free Dna ◽  
Dose Volume ◽  
Gu Toxicity ◽  
Patient Reported ◽  
Gi Toxicity ◽  
Grade 3 ◽  
To Receive

Abstract Background After radiation therapy (RT), circulating plasma cell-free DNA (cfDNA) released in response to RT damage to tissue can be measured within hours. We examined for a correlation between cfDNA measured during the first week of therapy and early and late gastrointestinal (GI) and genitourinary (GU) toxicity. Material and Methods Patients were eligible for enrollment if they planned to receive proton or photon RT for nonmetastatic prostate cancer in the setting of an intact prostate or after prostatectomy. Blood was collected before treatment and on sequential treatment days for the first full week of therapy. Toxicity assessments were performed at baseline, weekly during RT, and 6 months and 12 months after RT. Data were analyzed to examine correlations among patient-reported GI and GU toxicities. Results Fifty-four patients were evaluable for this study. Four (7%) and 3 (6%) patients experienced acute and late grade 2 GI toxicity, respectively. Twenty-two (41%) and 18 (35%) patients experienced acute and late grade 2 GU toxicity, respectively. No patients developed grade 3 or higher toxicity. Grade 2 acute GI toxicity, but not grade 2 acute GU toxicity, was significantly correlated with pre-RT cfDNA levels and on all days 1, 2, 3, 4, and 5 of RT (P < .005). Grade 2 late GI toxicity, but not GU toxicity, was significantly correlated with pre-RT cfDNA levels (P = .021). Conclusions Based on this preliminary study, cfDNA levels can potentially predict the subset of patients destined to develop GI toxicity during prostate cancer treatment. Given that the toxicity profiles of the various fractionations and modalities are highly similar, the data support the expectation that cfDNA could provide a biological estimate to complement the dose-volume histogram. A test of this hypothesis is under evaluation in a National Cancer Institute–funded multi-institutional study.

scholarly journals Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

2017 ◽  
Vol 7 (9) ◽  
pp. 1006-1017 ◽  
Author(s):  
Jane Goodall ◽  
Joaquin Mateo ◽  
Wei Yuan ◽  
Helen Mossop ◽  
Nuria Porta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Parp Inhibition ◽  
Prostate Cancer Treatment ◽  
Cell Free Dna ◽  
Free Dna ◽  
Circulating Cell Free Dna

scholarly journals Quantitative and Qualitative Analysis of Circulating Cell-Free DNA Can Be Used as an Adjuvant Tool for Prostate Cancer Screening: A Meta-Analysis

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Changqing Yin ◽  
Changliang Luo ◽  
Wei Hu ◽  
Xu Ding ◽  
Chunhui Yuan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Qualitative Analysis ◽  
Prostate Cancer Screening ◽  
Meta Analysis ◽  
Specific Antigen ◽  
Diagnostic Value ◽  
Qualitative Assessment ◽  
Cell Free Dna ◽  
Free Dna ◽  
Circulating Cell Free Dna

As part of “liquid biopsy,” lots of literature indicated the potential diagnostic value of circulating cell-free DNA (cfDNA) in the management of prostate cancer (PCa). However, the literature on the accuracy of cfDNA detection in PCa has been inconsistent. Hence, we performed this meta-analysis to assess the diagnostic value of cfDNA in PCa. A total of 19 articles were included in this analysis according to the inclusion and exclusion criteria. We then investigated two main subgroups in this meta-analysis, including qualitative analysis of abnormal level of cfDNA and qualitative analysis of single-gene methylation alterations. Overall, the results of quantitative analysis showed sensitivity of 0.73 (95% CI, 0.62–0.82) and specificity of 0.80 (95% CI, 0.70–0.87), with an area under the curve (AUC) of 0.83 (95% CI, 0.80–0.86). For qualitative assessment, the values were 0.34 (95% CI, 0.22–0.48), 0.99 (95% CI, 0.97–1.00), and 0.91 (95% CI, 0.88–0.93), respectively. Our results suggest the pooled specificity of each subgroup is much higher than the specificity of prostate-specific antigen (PSA). However, they are not recommended for PCa screening alone, because their sensitivities are not higher than the conventional serum biomarkers PSA. We conclude that analysis of cfDNA can be used as an adjuvant tool for PCa screening.

Sign in / Sign up

Export Citation Format

Share Document